Core Points - Tianchen Medical announced that the board of directors will postpone its re-election, and the terms of the board's specialized committees and senior management will be extended accordingly [1]

证券代码：688013 证券简称：天臣医疗 公告编号：2025-061 天臣国际医疗科技股份有限公司 关于董事会延期换届及独立董事任期届满 的提示性公告 公司现任独立董事陆志安先生、范明先生、金文龙先生的任期于2025年11 月9日届满且连任时间满六年，即将任期届满离任。鉴于各位独立董事任期届满 离任将导致公司独立董事人数少于董事会成员的三分之一，根据《上市公司独立 董事管理办法》和《公司章程》等相关规定，在董事会换届工作完成以前，陆志 安先生、范明先生、金文龙先生将按照法律法规等相关规定，继续履行独立董事 及相关董事会专门委员会委员职责，直至公司股东会选举产生新的独立董事。 1 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、公司董事会延期换届的情况 天臣国际医疗科技股份有限公司（以下简称"公司"）第二届董事会将于2025 年11月9日任期届满。鉴于相关换届工作尚在积极筹备中，为保证公司董事会相 关工作的连续性及稳定性，公司董事会将延期换届，董事会各专门委员会、高级 管理人员的任期将相应顺延。 在公司董事会换届选举工 ...

Summary of Key Points Core Viewpoint - Tianchen Medical (688013) has been actively repurchasing shares, with a total of 2,505,324 shares bought back, representing 3.09% of the total share capital, and a total expenditure of approximately 42.5 million yuan as of October 31, 2025 [1][3]. Trading Information - On October 31, 2025, Tianchen Medical's stock closed at 51.69 yuan, up 2.38%, with a turnover rate of 2.37% and a trading volume of 19,200 shares, resulting in a transaction value of 99.12 million yuan [1]. - The net outflow of funds from major investors was 360.49 thousand yuan, accounting for 3.64% of the total transaction value, while retail investors saw a net inflow of 1,619.33 thousand yuan, making up 16.34% of the total transaction value [1][3]. Company Announcements - Tianchen Medical initiated a share repurchase program on December 27, 2023, with an original plan to repurchase between 18 million yuan and 36 million yuan. This amount was later adjusted to a range of 46 million yuan to 80 million yuan, with the repurchase period extended to December 26, 2025 [1]. - The repurchased shares are intended for employee stock ownership plans or equity incentives, and the repurchase price ranged from 11.87 yuan to 21.00 yuan per share [1].

Core Points - Tianchen Medical (688013) closed at 51.69 yuan on October 31, 2025, down 7.13% from last week's 55.66 yuan [1] - The company's current market capitalization is 4.195 billion yuan, ranking 84th out of 126 in the medical device sector and 3768th out of 5163 in the A-share market [1] Company Announcements - Tianchen Medical initiated a share buyback on December 27, 2023, with an original plan to repurchase between 18 million yuan and 36 million yuan, which was later adjusted to a total buyback amount of 46 million yuan to 80 million yuan, extending the deadline to December 26, 2025 [2] - The funding sources for the buyback include self-owned funds and a special loan not exceeding 34.65 million yuan [2] - As of October 31, 2025, the company has repurchased a total of 2,505,324 shares, accounting for 3.09% of the total share capital, with a total expenditure of approximately 42.4989 million yuan, at a buyback price range of 11.87 yuan to 21.00 yuan per share [2][3] - No share buyback transactions were conducted in October 2025 [3]

Core Points - Tianchen Medical announced that it did not conduct any repurchase transactions in October 2025 [1] Summary by Category - **Company Announcement** - Tianchen Medical released a statement indicating no share repurchase activities took place in October 2025 [1]

回购方案首次披露日 2023/12/28由董事长、控股股东及实际控制人之 一陈望宇先生提议 回购方案实施期限 2023 年 12 月 27 日~2025 年 12 月 26 日 预计回购金额 4,600万元~8,000万元 回购用途 □减少注册资本 √用于员工持股计划或股权激励 □用于转换公司可转债 □为维护公司价值及股东权益 累计已回购股数 2,505,324股 累计已回购股数占总股本比例 3.09% 累计已回购金额 4,249.89万元 实际回购价格区间 11.87元/股~21.00元/股 重要内容提示： 一、回购股份的基本情况 天臣国际医疗科技股份有限公司（以下简称"公司"）于 2023 年 12 月 27 日 召开第二届董事会第十次会议，审议通过了《关于<公司以集中竞价交易方式回购 公司股份的方案>的议案》，同意公司以集中竞价交易方式回购公司股份，回购资 金总额不低于人民币 1,800 万元（含），不超过人民币 3,600 万元（含），回购价格 不超过人民币 30.00 元/股，回购期限自公司董事会审议通过回购方案之日起 12 个 月 内 。 具 体 内 容 详 见 公 司 于 2023 年 12 月 ...

Core Viewpoint - Tianchen Medical (688013.SH) has repurchased a total of 2.5053 million shares, representing 3.09% of the company's total share capital, with a total expenditure of approximately RMB 42.4989 million [1] Summary by Category Share Repurchase - The company has completed a share repurchase of 2.5053 million shares, which is 3.09% of its total share capital [1] - The highest price paid for the repurchased shares was RMB 21.00 per share, while the lowest price was RMB 11.87 per share [1] - The total funds used for the repurchase amounted to approximately RMB 42.4989 million, excluding transaction costs such as stamp duty and trading commissions [1]

Group 1 - The core viewpoint of the news is that Tianchen Medical has experienced significant stock price fluctuations and financial growth, with a notable increase in revenue and net profit year-on-year [1][2]. Group 2 - As of October 31, Tianchen Medical's stock price rose by 2.02% to 51.51 CNY per share, with a market capitalization of 4.18 billion CNY [1]. - The company has seen a year-to-date stock price increase of 219.28%, but has experienced a decline of 7.46% in the last five trading days and 13.05% in the last twenty days [1]. - Tianchen Medical's main business involves the research, innovation, and production of high-end surgical staplers, with 77.92% of revenue coming from non-powered products and 22.08% from powered products [1]. - As of September 30, the number of shareholders increased by 11.48% to 4,624, while the average circulating shares per person decreased by 10.29% to 17,550 shares [2]. - For the period from January to September 2025, Tianchen Medical achieved a revenue of 244 million CNY, representing a year-on-year growth of 20.66%, and a net profit of 71.95 million CNY, up 68.29% year-on-year [2]. - The company has distributed a total of 211 million CNY in dividends since its A-share listing, with 179 million CNY distributed over the past three years [2].

Core Insights - The medical device sector experienced a slight increase of 0.37% on October 24, with Mai Lande leading the gains [1] - The Shanghai Composite Index closed at 3950.31, up 0.71%, while the Shenzhen Component Index closed at 13289.18, up 2.02% [1] Medical Device Sector Performance - Top gainers included: - Mai Lande (688273) with a closing price of 41.92, up 6.31%, trading volume of 29,300 hands, and a transaction value of 121 million yuan [1] - Xiangyu Medical (688626) at 53.21, up 6.10%, with a trading volume of 41,100 hands and a transaction value of 216 million yuan [1] - Xiangsheng Medical (688358) at 35.27, up 4.75%, with a trading volume of 38,400 hands and a transaction value of 136 million yuan [1] - Other notable gainers included: - Aohua Endoscopy (688212) at 50.59, up 4.74%, with a transaction value of 225 million yuan [1] - Weisi Medical (688580) at 49.10, up 4.71%, with a transaction value of approximately 99.8 million yuan [1] Decliners in Medical Device Sector - Notable decliners included: - Chenguang Medical (920300) at 17.51, down 8.80%, with a trading volume of 124,000 hands [2] - Toukeng Life (300642) at 22.95, down 5.40%, with a trading volume of 175,700 hands [2] - Haitai New Light (688677) at 48.50, down 5.05%, with a trading volume of 38,800 hands [2] - Other significant decliners included: - Sino Medical (688108) at 28.00, down 4.73%, with a trading volume of 263,700 hands [2] - Tianchen Medical (688013) at 55.66, down 3.98%, with a trading volume of 19,200 hands [2] Capital Flow in Medical Device Sector - The medical device sector saw a net outflow of 654 million yuan from major funds, while retail investors contributed a net inflow of 455 million yuan [2]

Macro Highlights - The main goals for the "14th Five-Year Plan" period include significant achievements in high-quality development, substantial improvement in technological self-reliance, breakthroughs in comprehensive reforms, enhanced social civilization, improved quality of life, major progress in building a beautiful China, and a more solid national security barrier [1] - By 2035, the aim is to significantly elevate China's economic, technological, defense, and comprehensive national strength, with per capita GDP reaching the level of moderately developed countries, leading to a happier and better life for the people and basic realization of socialist modernization [1] Trade Relations - The Ministry of Commerce announced that a Chinese delegation led by Vice Premier He Lifeng will engage in economic and trade consultations with the U.S. in Malaysia from October 24 to 27, focusing on important issues in Sino-U.S. economic relations [1] EU Sanctions Response - The Ministry of Commerce expressed strong dissatisfaction and firm opposition to the EU's decision to sanction Chinese companies, including large oil refineries and traders, during the 19th round of sanctions against Russia, emphasizing the need to protect the legitimate rights and interests of Chinese enterprises [2] State-Owned Enterprises Planning - The State-owned Assets Supervision and Administration Commission held a meeting to discuss the "14th Five-Year Plan" for central enterprises, emphasizing the need to align with the strategic mission assigned by the Party Central Committee and to enhance core functions and competitiveness [3] - The meeting highlighted the importance of optimizing layout and structural adjustments in line with national needs and industry trends, and improving the quality of planning through thorough research and unified thinking [3] Foreign Exchange Management - The Deputy Director of the State Administration of Foreign Exchange encouraged the implementation of innovative and integrated exploratory policies in Shanghai, focusing on the use of AI and big data to enhance foreign exchange services [4] - The aim is to improve the cross-border financial service capabilities of Shanghai while balancing financial openness and security [4] Company News - Huagong Technology reported a 40.92% year-on-year increase in net profit for the first three quarters and is planning to issue H-shares for listing in Hong Kong [8] - Yangjie Technology terminated its acquisition of 100% equity in Better Electronics [8] - Xinda Securities received approval for the issuance of up to 10 billion yuan in technology innovation corporate bonds [8] - Shuangliang Energy plans to raise no more than 1.292 billion yuan for projects related to zero-carbon intelligent manufacturing [8] - New Lai Materials' subsidiary plans to invest 2 billion yuan in semiconductor core component projects [8] - Chuanfa Longmang's subsidiary intends to invest 366 million yuan in a 100,000 tons/year lithium dihydrogen phosphate project [8] - Steel Research High-tech plans to establish a subsidiary and new industrial base in Saudi Arabia [8] - Aote Electronics intends to terminate the smart integration project for intelligent outlets [8] - Shengyi Electronics expects a year-on-year net profit increase of 476% to 519% for the first three quarters [8] - Other companies reported significant year-on-year net profit growth, including Tianeng Heavy Industry (1359.03%), Te Yi Pharmaceutical (985.18%), and Zhuanlei Technology (598.09%) [8][9]